Join us in congratulating the following members on earning the Fellows of ASCO (FASCO) distinction last quarter! We are grateful for their extraordinary volunteer service, dedication, and commitment to ASCO. Learn more: brnw.ch/21wQwer

Thrilled to share a project that we envisioned over a decade ago to perform high purity/high specificity molecular analysis of circulating tumor cells! Led by the brilliant Marina Sharifi and Jamie Sperger AACR Funded by PCF Science NIH CDMRP

Thank you to Misha Beltran and Himanshu Nagar for organizing this year’s Feng Symposium. Felix would have loved to catch up with his friends and talk about a new crazy way to change the world. A reminder to collaborate and take care of each other. UCSF Helen Diller Family Comprehensive Cancer Ctr ASCO ASTRO

Join us at #GU25 L34 TIP highlighting the PREDICT trial. DNA/RNA biomarker based precision medicine trial through the ⁦Alliance for Clinical Trials in Oncology⁩. Actively accruing patients with mCRPC post ARPI. ⁦Misha Beltran⁩ ⁦OncoAlert⁩ ⁦Alan Tan⁩

I am grateful to UroToday.com for hosting me on their digital platform. It was a wonderful opportunity to share insights on our recent publication about EZH2 activity in advanced #ProstateCancer subtypes. #BeltranLab PCF Science bit.ly/418kjQe

🚀 Here we go for Transatlantic Exchanges with Gustave Roussy, Dana-Farber, Institut Servier and Toni Choueiri, MD.

“Unravelling PSMA Biology” WEBINAR 👉Live, Free & Interactive: link.prostic.org/webinar PSMA Theranostics is booming and it is only the beginning. Let’s unravel PSMA biology together. Join us for a free and an enlightening live session with world-renowned experts. Explore the

Excited to share our latest article on exploring the surfaceome and targeting surface antigens in prostate cancer! Huge thanks to Misha Beltran, Johann de Bono, Tarek Taha and Balaji for all the support! 🙌 nature.com/articles/s4158…

Very informative work from our Dana-Farber Lank Center for Genitourinary Oncology and Dana-Farber colleague Misha Beltran and her team + #DeBono’s team on how to target the prostate cancer #surfacome Balaji Nature Portfolio nature.com/articles/s4158…

📢 Just published in Annals of Oncology: “ESMO Precision Oncology Working Group Recommendations on the Structure and Quality Indicators for Molecular Tumour Boards in Clinical Practice”. sciencedirect.com/science/articl… Ben Westphalen ESMO - Eur. Oncology

CircRNA is the most bizarre yet fascinating RNA. Our work of circRMST in prostate and lung cancer is now online at Cancer Cell. Great teamwork with Misha Beltran and Jun Qing and many others. Thanks for the support from Terry Fox Research Institute Prostate Cancer Foundation The Princess Margaret Cancer Foundation CIHR and more

New research in Cancer Cell by Dana-Farber and Princess Margaret Cancer Centre Research identifies circRMST, a circular RNA abundant in NETs of the prostate and lung. Essential for tumor growth, it boosts ASCL1 expression by interacting with SOX2 & NKX2-1. Misha Beltran ➡️bit.ly/4ilNPbZ

It was an incredible experience presenting at #AACR25. Thank you to my mentor Misha Beltran and to PCF Science and CDMRP for their support. Grateful to DFCI for sharing!

Prostate cancer at #ASCO25: Talazoparib + tazemetostat showed expected bone marrow suppression & limited benefit in pre-treated, biomarker-unselected patients. Research underway to ID those most likely to respond. Atish Choudhury, MD PhD Dana-Farber Lank Center for Genitourinary Oncology

KLK2 is HOT right now! We evaluated RNA expression across histologies, sites of mets, and disease states in prostate cancer. Check it out! #ASCO25 ⁦UC San Diego Health Moores Cancer Center⁩ ⁦Caris Life Sciences⁩ ⁦OncoAlert⁩ ⁦Misha Beltran⁩ ⁦Neeraj Agarwal, MD, FASCO⁩

Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer Nature Communications rdcu.be/euijO Team science led by Kei Mizuno #BeltranLab Dana-Farber Lank Center for Genitourinary Oncology PCF Science

Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair–deficient Metastatic Castration-resistant Prostate Cancer euoncology.europeanurology.com/article/S2588-… This international retrospective study evaluated the effectiveness of anti-PD-(L)1 immune checkpoint inhibitors in 93

Just published European Urology: The rapidly evolving standard of care for prostate cancer - toward biomarker-driven strategies with promising developments on the horizon doi.org/10.1016/j.euru… Proud to collaborate with A. Cimadamore, J. de Bono, Misha Beltran,Adam Sharp

Pathology workup for metastatic #CRPC: Focus on neuroendocrine transformation. Misha Beltran Dana-Farber joins Andrea Miyahira Prostate Cancer Foundation discussing a standardized framework for pathologic workup of #mCRPC biopsies. The framework proposes initial morphologic classification,

A new model for mCRPC that adds ctDNA-based genomic alterations to clinical data improves overall survival prediction by ~30%. AR, PTEN, TP53, MYC among key drivers. A step closer to precision trials. #ProstateCancer #Oncology Misha Beltran Emmanuel Antonarakis Matt Galsky